House passes bills to promote access to drug price data
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance. One bill (S. 2554) applies to private health plans and the other (S. 2553) to patients in Medicare Advantage and Medicare Part D plans. Both bills passed the Senate this month and now go to the president for his signature. Some health insurance contracts prevent pharmacists from informing patients when the cash price for their prescription costs less than their insurance cost-sharing arrangement unless the individual asks.
Related News Articles
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…